The Investment Council's current calls across every ticker we've researched.
Updated May 30, 2026. Click any ticker for the full council reasoning.
Buy (4)
Ticker | Verdict | Conviction | One-line reason | Analysis |
|---|---|---|---|---|
$CHWY | STRONG_BUY | HIGH | INTACT moat (record 83% Autoship, NSPAC +4%) + PERCEIVED_ONLY crisis (54% drawdown on non-operational catalysts) + CHEAP at 14.3x adj. EBITDA (bottom decile), PEG 0.61 | |
$SHAK | BUY | MED | INTACT moat + HIGHLY_CAPABLE management (Lynch playbook) + REASONABLE multiple + insider cluster including Danny Meyer's ~$2M check | |
$RBLX | BUY | MED | INTACT moat + HIGHLY_CAPABLE management + REASONABLE multiple at historical floor. Verification friction is solvable; June 8 Kids/Select launch is the proof point. | |
BUY | MED | INTACT moat + PERCEIVED_ONLY crisis (category-wide SSS decline) + REASONABLE valuation at Chipotle parity |
Wait (7)
Ticker | Verdict | Conviction | One-line reason | Analysis |
|---|---|---|---|---|
$AEO | WAIT | MED | INTACT moat migrating to Aerie (+25% comps) + CHEAP at 0.6x revenue, but two binary unknowns (tariff mitigation + AE brand reboot) resolve in September Q2 print | |
$CAG | WAIT | MED | CHEAP at 8.5x fwd P/E (34% peer discount) + 10.3% covered dividend yield, but ERODING moat (Marie Callender's decline, pricing power limited) + new CEO starts June 1 + July 9 Q4 earnings = decider | |
$RH | WAIT | MED | Intact moat, fixable crisis, but June 4 Q1 earnings is the decider | |
$RIVN | WAIT | MODERATE | Beloved product, brutal unit economics — wait for R2 proof before buying | |
$DPZ | WAIT | MED | Intact moat + cheap at 18x, but July 16 Q2 earnings is a binary catalyst that will either restore growth narrative or confirm structural deceleration | |
$DNUT | WAIT | MED | Moat eroding (channel loss, not brand) but Hees board upgrade + 40-75% peer discount; 5.5x leverage demands Q2 confirmation |
$RVLV
WAIT
MED
INTACT moat + CHEAP at 1.1x revenue with 53% gross margins, but two binary unknowns (influencer lawsuit arbitration + OnTrac shipping fix) resolve by August 5 earnings
$GIS
WAIT
MED
Genuinely cheap at 8.2x earnings but eroding moat, hybrid crisis, and mixed management capability create negative trajectory — July 1 FY2027 guidance is the decider
⛔ Avoid (21)
Ticker | Verdict | Conviction | One-line reason | Analysis | |
|---|---|---|---|---|---|
$LULU | AVOID | MED | Moat eroding — three see-through scandals in 24 months, 60% unanswered BBB complaints, Vuori/Alo at 52% shopper overlap, even at bottom-decile multiple | ||
$SNAP | AVOID | MED | Moat eroding — NA DAU bleeding 98M → 92M, eCPMs -12%, ad-business growth +3% vs META +33%, even at 5-yr-low P/S | ||
$CELH | AVOID | MED | Moat eroding — namesake brand growth decelerated 100%+ → 5.6% YoY, Kirkland clone at 55% per-can discount testing pricing power, gross margin -400 bps (p=0.022) | ||
$PLNT | AVOID | MED | Moat eroding — net new January adds -36% YoY, four consecutive quarters of same-club deceleration, Crunch executing $9.95 land-grab (+48% YoY leasing), interim CFO running first-time turnaround | ||
$CPB | AVOID | MED | Eroding moat in legacy soup/snacks — cheap at 8.6× EV/EBITDA but ERODING moat short-circuits to AVOID; June 8 Q3 is the decider | ||
$PTON | AVOID | MEDIUM | Subscriber base shrinking 7.6% YoY with no visibility on stabilization; buying a shrinking franchise at a discount is a value trap | ||
$LCID | AVOID | MEDIUM | Eroding moat: operational gap to Rivian widening, not narrowing | ||
$GPRO | AVOID | MED | Eroding moat + existential crisis; price at expected value with no margin of safety | ||
$ELF | AVOID | MED | Moat eroding: pricing power absent, organic growth stalled 77% to 3-5% | ||
$BMBL | AVOID | MEDIUM | Eroding moat; cheap but unproven 2.0 | ||
$CMG | AVOID | MED | Moat eroding — brand friction (portion controversy), margin compression (16.9%→12.9%), competitive share loss (CAVA +9.7% vs CMG +0.5%) | ||
$COTY | AVOID | MED | Moat eroding: Gucci license expires June 2028 ($550M revenue to L'Oreal), Prestige LFL -5% vs category +4-6%, Consumer Beauty in structural freefall -9% LFL | ||
$WHR | AVOID | MED | Eroding moat + insufficient management override cheap valuation | ||
$NCLH | AVOID | MED | Norwegian brand moat eroding — sole negative net yield among major cruise operators in healthy demand; July 30 Q2 is the re-eval | ||
$JACK | AVOID | MED | eroding moat overrides cheap valuation and promising new CEO | ||
$DKNG | AVOID | MED | INTACT moat but ADEQUATE management navigating real crisis; wait for proof | ||
$KSS | AVOID | MED | Eroding moat (Sephora leased) + structural share loss to off-price + fair valuation offers no margin of safety | ||
$BBWI | AVOID | MED | Eroding moat from promotional dependency and margin compression forces AVOID despite cheap valuation — Q2 FY26 earnings in August is the decider | ||
$EPC | AVOID | MED | EPC offers a cheap price and a credible restructuring narrative, but a confirmed eroding moat in wet shave makes this a value trap to avoid. | ||
$NWL | AVOID | MED | Eroding moat overrides cheap valuation; insider selling confirms | ||
$THO | AVOID | MED | Eroding moat — 65% 1-star complaint share (vs 45% Winnebago, p<0.001), 300bps margin compression, warranty refusal pattern converting defects to trust destruction | ||
$NKE | AVOID | MEDIUM | Eroding moat dominates reasonable valuation — wait for margin proof before buying | ||
$W | AVOID | MED | Governance ceiling + leverage compress upside despite cheapness |
$JACK
AVOID
MED
eroding moat overrides cheap valuation and promising new CEO
🕯 Pending IC Analysis (2)
The TR Research below has shipped; each ticker is queued for the Investment Council's 4-specialist filter (Moat / Crisis / Capability / Valuation). Verdicts land here as each council completes.
Ticker | TR Research | Status |
|---|---|---|
$OLLI | Council queued | |
$ANF | Council queued |
How the Council Works
Every ticker that ships TR Research goes through a 4-specialist filter before it lands on this board. The specialists each answer one question, in their own lane, with their own evidence — and a chair integrates them into a single verdict.
The Moat Auditor asks whether the company's core value — product, brand, customer loyalty, competitive position — is intact, eroding, or damaged versus 12 months ago. If the moat is ERODING or DAMAGED, the matrix short-circuits to AVOID regardless of how cheap the multiple looks.
The Crisis Diagnostician asks whether the trouble priced into the stock is perceived-only, real-but-fixable, or real-and-serious.
The Capability Assessor runs only when the Crisis Diagnostician says "real-but-fixable." HIGHLY_CAPABLE means you've seen this team solve a structurally similar problem before. ADEQUATE means they're plausibly capable but unproven. INSUFFICIENT short-circuits the matrix to AVOID.
The Valuation Analyst runs in parallel as an independent gate. The multiple has to be CHEAP or REASONABLE for the matrix to greenlight a BUY. EXPENSIVE forces WAIT. OVERPRICED forces AVOID even when the fundamentals are great.
The Chair integrates the four reads via a deterministic decision matrix. INTACT + PERCEIVED_ONLY + CHEAP = STRONG_BUY. INTACT + REAL_BUT_FIXABLE + HIGHLY_CAPABLE + REASONABLE = BUY. ERODING or DAMAGED at the top short-circuits to AVOID. When the specialists disagree — especially Moat ERODING vs. Valuation CHEAP — the chair's working rule is that the market may have correctly priced erosion that hasn't yet shown up in headline numbers.
This board updates every time we publish new research. To get the verdict on each new ticker the moment it lands, subscribe to Turnaround Radar.